— Next-generation assay aids in diagnosing heart attacks faster and more accurately, and is enabled on the company’s newest analyzer, the VITROS(R) XT 7600 Integrated System
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced CE Mark for its next-generation VITROS(R) High Sensitivity Troponin I assay. This new assay is the latest addition to the company’s robust cardiology menu and is a critical tool for clinicians who are seeking improved strategies to more rapidly and accurately identify patients suffering from a heart attack. Ortho’s VITROS High Sensitivity Troponin I assay also aids in identifying low-risk patients who may be safely discharged to help reduce the cost of care and alleviate the burden on hospital resources.
“We’re proud to bring the VITROS High Sensitivity Troponin I assay to market in providing hospitals with more reliable and precise diagnostics for cardiac care,” said Heidi Casaletto, head of portfolio strategy and marketing at Ortho. “Improved analytical performance complies with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) definition of high sensitivity, enabling use with rapid rule-in/rule-out diagnostic protocols and allowing hospitals to more quickly diagnose and treat patients.”
According to the World Health Organization, there are 9.4 million deaths per year due to ischemic heart disease[1]. In the U.S. alone, 750,000 patients suffer from a heart attack every year[2]. A heart attack is an urgent, time-critical emergency that requires the fastest intervention possible to preserve the best patient outcomes possible.
The VITROS High Sensitivity Troponin I assay can run on Ortho’s latest analyzer, the VITROS(R) XT 7600 Integrated System, as well as the VITROS(R) ECi/ECiQ Immunodiagnostic Systems, the VITROS(R) 3600 Immunodiagnostic System and the VITROS(R) 5600 Integrated System.
The VITROS High Sensitivity Troponin I assay is available commercially in all countries that accept CE Mark, including Chile and Australia.
For more information, follow Ortho on LinkedIn ( https://c212.net/c/link/?t=0&
[1] WHO Disease burden and mortality estimates, 2016. Downloaded from https://www.who.int/
[2] Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho’s high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho’s blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho’s purpose is to improve and save lives with diagnostics, and it does that by reimagining what’s possible. This is what has defined Ortho for more than 75 years, and it’s what drives Ortho forward. For more information, visit www.orthoclinicaldiagnost
ics.com.
(C) Ortho Clinical Diagnostics 2019
PR-04702
SOURCE: Ortho Clinical Diagnostics
